Clinical trials: Chronic Urticaria
Chronic Spontaneous Urticaria
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) inadequately controlled by non-sedating second generation…
- Trial name
- EMBARQ-CSU2 (NCT06455202)
- Testing
- barzolvolimab
- Where
- 245 sites in United States, Australia and 20 more
- Volunteers
- 976 people
- Sponsor
- Celldex Therapeutics
Chronic Spontaneous Urticaria
Remibrutinib in Real-world Clinical Practice
Prospective, multi-country, non-interventional study in patients with CSU where the treatment decision prior enrolment has been made to either escalate current sgH1-AHs treatment or escalate/switch current treatment to…
- Trial name
- REASSERT (NCT07358364)
- Where
- United States
- Volunteers
- 3,280 people
- Sponsor
- Novartis Pharmaceuticals
Familial Cold Autoinflammatory Syndrome
Study of Safety, Tolerability and Efficacy of DFV890 in Participants With Familial Cold Auto-inflammatory Syndrome (FCAS)
The purpose of this phase II study was to assess the safety, tolerability and efficacy of DFV890 in participants with FCAS.
- Trial name
- DFV890-FCAS (NCT04868968)
- Testing
- DFV890
- Where
- 3 sites in United States, France and 1 more
- Volunteers
- 4 people
- Sponsor
- Novartis Pharmaceuticals
Allergic Rhinoconjunctivitis, Chronic Urticaria
Pharmacokinetic Study of Bilastine in Children From 2 to < 12 Years of Age With Either Allergic Rhinoconjunctivitis (AR) or Chronic Urticaria (CU)
The conduct of this clinical trial is aimed at determining the most suitable dose regimen for children in different age groups, and secondarily to assess the safety and tolerability of bilastine in this paediatric population…
- Trial name
- NCT01081574
- Testing
- Bilastine
- Where
- 7 sites in Australia, Germany and 1 more
- Volunteers
- 36 people
- Sponsor
- Faes Farma, S.A.
Urticaria
A Study of Quilizumab Versus Placebo in Patients With Refractory Chronic Spontaneous Urticaria
This multicenter, randomized, double-blind, placebo-controlled, parallel-group study will assess the efficacy and safety of additional quilizumab therapy in adult patients with Chronic Spontaneous Urticaria resistant to…
- Trial name
- NCT01987947
- Testing
- Quilizumab
- Where
- 3 sites in Canada, Germany
- Volunteers
- 32 people
- Sponsor
- Genentech, Inc.
Cryopyrin Associated Periodic Syndrome
The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada
This study will assess the safety, tolerability and efficacy of canakinumab treatment in Canadian patient diagnosed with cryopyrin-associated periodic syndrome over a period of 18 months.
- Trial name
- NCT01105507
- Testing
- canakinumab (company code: ACZ885D)
- Where
- 2 sites in Canada
- Volunteers
- 4 people
- Sponsor
- Novartis Pharmaceuticals
Atopic Dermatitis, Atopic Dermatitis Eczema
Bioavailability and Tolerability of Fexofenadine Hydrochloride Topical Lotion 1%
The investigational lotion is envisaged as an short- and long term "Ease \& Prevent" monotherapy for adults and children with mild to moderate eczema.
- Conditions
- Atopic Dermatitis, Atopic Dermatitis Eczema, Atopic Rash, Rash
- Trial name
- ATOFEX-1 (NCT05461456)
- Testing
- Fexofenadine Hydrochloride Topical Lotion 1% (OP2101)
- Where
- Bangladesh
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- OrchestratePharma GmbH
Cold Urticaria
Dupilumab for the Treatment of Chronic Inducible Cold Urticaria in Patients Who Remain Symptomatic Despite the Use of H1-antihistamine (LIBERTY-CINDU CUrIADS)
Primary Objective: To demonstrate the efficacy of dupilumab in adult and adolescent participants with primary acquired chronic inducible cold urticaria (ColdU) who remain symptomatic despite the use of an H1-antihistamine…
- Trial name
- NCT04681729
- Testing
- Dupilumab SAR231893, Non sedating H1-antihistamine
- Where
- 33 sites in United States, Argentina and 3 more
- Volunteers
- 82 people
- Sponsor
- Sanofi
Urticaria
A Comparative Double-blind, Double-dummy Study of Desloratadine (DL) 5 mg Once Daily, Cetirizine 10 mg Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03736)
This was a randomized, double-blind, parallel-group, multicenter study that used both an active control (cetirizine) and a placebo control to evaluate desloratadine 5 mg once daily during a 28-day treatment period.
- Trial name
- NCT00751166
- Testing
- Desloratadine, Cetirizine
- Volunteers
- 149 people
- Sponsor
- Organon and Co
Chronic Spontaneous Urticaria (CSU)
A Study of Efficacy and Safety of TLL-018 in CSU Participants With Inadequate Response to 2nd-generation H1-AHs
The goal of this clinical trial is to learn if different doses of TLL-018 works to treat in moderate-to-severe chronic spontaneous urticaria (CSU) participants . It will also learn about the safety of TLL-018.
- Trial name
- NCT07764003
- Testing
- TLL-018 tablets
- Volunteers
- 140 people
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd
Chronic Inducible Urticaria
A Study of CDX-0159 in Patients With Chronic Inducible Urticaria
The purpose of this study is to assess the clinical effect, the pharmacodynamics, the safety, and the pharmacokinetics of barzolvolimab (CDX-0159) in patients with Chronic Inducible Urticaria who remain symptomatic despite the…
- Trial name
- NCT05405660
- Testing
- barzolvolimab
- Where
- 76 sites in United States, Bulgaria and 9 more
- Volunteers
- 196 people
- Sponsor
- Celldex Therapeutics
Chronic Spontaneous Urticaria
Efficacy and Safety of LP-003 in Patients With CSU Who Remain Symptomatic Despite Antihistamine (H1) Treatment
The study is a Phase II, multicenter, randomized, double-blind study to evaluatethe efficacy and safety of LP-003 administered subcutaneously as an add-on therapy for the treatment of adult patients aged 18-75 who have been…
- Trial name
- NCT06228560
- Testing
- LP-003, Omalizumab
- Where
- 17 sites in China
- Volunteers
- 202 people
- Sponsor
- Longbio Pharma
Chronic Spontaneous Urticaria (CSU), Chronic Idiopathic Urticaria
A Study to Assess the Efficacy and Safety of THB335 in Adults With Chronic Spontaneous Urticaria (CSU)
THB335-201 is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group, multicenter study in adults with CSU who remain symptomatic despite standard-of-care treatment.
- Trial name
- NCT07766499
- Testing
- THB335 Lower Dose, THB335 Higher Dose
- Volunteers
- 81 people
- Sponsor
- Calixis Inc.
Chronic Idiopathic Urticaria
CUTE (Chronic Urticaria Treatment Evaluation)
A study to compare the clinical efficacy and safety of Levocetirizine vs. Desloratadine in patients suffering from Chronic Idiopathic Urticaria (CIU) measured by the mean pruritus severity score over the first week of treatment
- Trial name
- NCT00264303
- Testing
- Levocetirizine, Desloratadine
- Where
- 80 sites in Belgium, France and 7 more
- Volunteers
- 886 people
- Sponsor
- UCB Pharma
Rhinitis, Urticaria
Evaluation of Desloratadine When Used in Patients With Either Allergic Rhinitis or Chronic Idiopathic Urticaria
Eligible patients will be prescribed Desloratadine 1 tablet of 5 mg once daily. Patients will be asked to follow-up for a final visit after 14 days (Day 15) where the safety, tolerability and clinical efficacy will be measured.
- Trial name
- Aerius (NCT00724698)
- Testing
- Desloratadine
- Volunteers
- 3,011 people
- Sponsor
- Organon and Co
NALP3 Mutation
Safety, Efficacy, Pharmacokinetics, Pharmacodynamics of ACZ885 in Patients With NALP3 Mutations and Clinical Symptoms
This study will investigate the clinical efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of ACZ885, administered intravenously and subcutaneously to patients with NALP3 mutations whose clinical symptoms are…
- Trial name
- NCT00487708
- Testing
- canakinumab
- Where
- 10 sites in France, Germany and 3 more
- Volunteers
- 34 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Spontaneous Urticaria
Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab
The purpose of this extension study was to establish efficacy and safety of ligelizumab. This was assessed in adult and adolescent chronic spontaneous urticaria (CSU) patients who had completed a preceding ligelizumab study and…
- Trial name
- NCT04210843
- Testing
- Ligelizumab
- Where
- 273 sites in United States, Argentina and 43 more
- Volunteers
- 1,033 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Spontaneous Urticaria
Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU)
This trial will be performed as a three-part dose escalating clinical trial where Parts 1 is open label and Parts 2 and 3 are randomized, double-blinded, and placebo-controlled.
- Trial name
- BEACON (NCT06162728)
- Testing
- Briquilimab
- Where
- 23 sites in United States, Germany
- Volunteers
- 87 people
- Sponsor
- Jasper Therapeutics, Inc.
Chronic Idiopathic Urticaria, Urticaria
The Efficacy and Safety of Desloratadine With Levocetirizine in Treatment of Chronic Idiopathic Urticaria
Objective: To compare the efficacy of desloratadine 5mg (Denosin®) and levocetirizine 5mg (Xyzal®) once daily in the treatment of patients with CIU over 6 weeks.
- Trial name
- NCT00346606
- Testing
- Denosin® and Xyzal®
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Lotus Pharmaceutical
Chronic Spontaneous Urticaria
Trial of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria.
This Phase III Trial is Meant to Evaluate the Efficacy, and Safety of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria.
- Trial name
- NCT07402213
- Testing
- JYB1904
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Jemincare